PTC Therapeutics Management
Management criteria checks 2/4
PTC Therapeutics' CEO is Matt Klein, appointed in Mar 2023, has a tenure of 1.08 years. total yearly compensation is $5.01M, comprised of 11.9% salary and 88.1% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth €1.14M. The average tenure of the management team and the board of directors is 7.2 years and 8.8 years respectively.
Key information
Matt Klein
Chief executive officer
US$5.0m
Total compensation
CEO salary percentage | 11.9% |
CEO tenure | 1.1yrs |
CEO ownership | 0.06% |
Management average tenure | 7.2yrs |
Board average tenure | 8.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$579m |
Dec 31 2023 | n/a | n/a | -US$627m |
Sep 30 2023 | n/a | n/a | -US$642m |
Jun 30 2023 | n/a | n/a | -US$618m |
Mar 31 2023 | n/a | n/a | -US$571m |
Dec 31 2022 | US$5m | US$598k | -US$559m |
Compensation vs Market: Matt's total compensation ($USD5.01M) is above average for companies of similar size in the German market ($USD1.61M).
Compensation vs Earnings: Insufficient data to compare Matt's compensation with company performance.
CEO
Matt Klein (50 yo)
1.1yrs
Tenure
US$5,009,299
Compensation
Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 1.1yrs | US$5.01m | 0.062% $ 1.1m | |
Co-Founder | 26.3yrs | US$7.16m | 0.097% $ 1.8m | |
Co-Founder | 26.3yrs | US$553.96k | 0.016% $ 294.6k | |
Chief Technical Operations Officer | 5.3yrs | US$2.67m | 0.054% $ 986.1k | |
Chief Business Officer | 9yrs | US$2.99m | 0.025% $ 451.9k | |
Chief Financial Officer | less than a year | no data | 0.010% $ 183.7k | |
Senior VP | 4.8yrs | US$1.70m | 0.022% $ 406.8k | |
Investor Relations Officer | no data | no data | no data | |
Executive VP & Chief Legal Officer | 12.1yrs | US$4.29m | 0.064% $ 1.2m | |
Vice President of Corporate Communications | no data | no data | no data | |
Senior Vice President of Human Resources | 3.5yrs | no data | no data | |
Senior Vice President of Global Regulatory Affairs | 9.3yrs | no data | no data |
7.2yrs
Average Tenure
59yo
Average Age
Experienced Management: BH3's management team is seasoned and experienced (7.2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 1.1yrs | US$5.01m | 0.062% $ 1.1m | |
Co-Founder | 1.1yrs | US$7.16m | 0.097% $ 1.8m | |
Co-Founder | 26.3yrs | US$553.96k | 0.016% $ 294.6k | |
Independent Chairman of the Board | 22.7yrs | US$908.42k | 1.96% $ 35.8m | |
Independent Director | 18.3yrs | US$488.46k | 0.0085% $ 155.0k | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Independent Director | 5.3yrs | US$491.46k | 0.0094% $ 171.8k | |
Member of Scientific Advisory Board | 20.4yrs | no data | no data | |
Independent Director | 8.8yrs | US$468.96k | 0.0085% $ 155.0k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 5.3yrs | US$463.96k | 0.0077% $ 140.0k |
8.8yrs
Average Tenure
63yo
Average Age
Experienced Board: BH3's board of directors are considered experienced (8.8 years average tenure).